Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Overview 8 Therapeutics Development 9 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Stage of Development 9 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Therapy Area 10 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Indication 11 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Companies 15 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Universities/Institutes 18 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Companies Involved in Therapeutics Development 27 Alligator Bioscience AB 27 Apexigen, Inc. 28 Apogenix GmbH 29 Boehringer Ingelheim GmbH 30 Bristol-Myers Squibb Company 31 Celldex Therapeutics, Inc. 32 F. Hoffmann-La Roche Ltd. 33 Kyowa Hakko Kirin Co., Ltd. 34 Novartis AG 35 Seattle Genetics, Inc. 36 Zyrnat Biotherapeutics SL 37 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Drug Profiles 38 2C-10 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 ADC-1013 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 APG-1233 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 APX-005M - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 BI-655064 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 bleselumab - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 BMS-986090 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 CFZ-533 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 FFP-104 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 KGYY-15 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Monoclonal Antibodies to Agonize CD40 for Lymphoma - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 RG-7876 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 SEA-CD40 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 ZY-11 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Dormant Projects 57 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Discontinued Products 60 Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Featured News & Press Releases 61 Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 61 Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 61 Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn’s Disease with anti-CD40 Monoclonal Antibody 62 Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 62 Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 63 Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M 64 May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform 64 Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial 65 Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial 65 Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors 66 Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply 66 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69

List of Tables Number of Products under Development for, H1 2016 9 Number of Products under Development by Therapy Area, H1 2016 10 Number of Products under Development by Indication, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Assessment by Monotherapy/Combination Products, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Pipeline by Alligator Bioscience AB, H1 2016 27 Pipeline by Apexigen, Inc., H1 2016 28 Pipeline by Apogenix GmbH, H1 2016 29 Pipeline by Boehringer Ingelheim GmbH, H1 2016 30 Pipeline by Bristol-Myers Squibb Company, H1 2016 31 Pipeline by Celldex Therapeutics, Inc., H1 2016 32 Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 33 Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 34 Pipeline by Novartis AG, H1 2016 35 Pipeline by Seattle Genetics, Inc., H1 2016 36 Pipeline by Zyrnat Biotherapeutics SL, H1 2016 37 Dormant Projects, H1 2016 57 Dormant Projects (Contd..1), H1 2016 58 Dormant Projects (Contd..2), H1 2016 59 Discontinued Products, H1 2016 60 List of Figures Number of Products under Development for, H1 2016 9 Number of Products under Development by Therapy Area, H1 2016 10 Number of Products under Development by Top 10 Indication, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 25

Alligator Bioscience AB Apexigen, Inc. Apogenix GmbH Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celldex Therapeutics, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Novartis AG Seattle Genetics, Inc. Zyrnat Biotherapeutics SL